BackgroundApproximately 20% of people with cirrhosis develop ascites. Several di erent treatments are available; including, among others, paracentesis plus fluid replacement, transjugular intrahepatic portosystemic shunts, aldosterone antagonists, and loop diuretics. However, there is uncertainty surrounding their relative e icacy.
ObjectivesTo compare the benefits and harms of di erent treatments for ascites in people with decompensated liver cirrhosis through a network meta-analysis and to generate rankings of the di erent treatments for ascites according to their safety and e icacy.
Search methodsWe searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trials registers until May 2019 to identify randomised clinical trials in people with cirrhosis and ascites.
Selection criteriaWe included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and ascites. We excluded randomised clinical trials in which participants had previously undergone liver transplantation.
Data collection and analysisWe performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio (HR) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and Care Excellence Decision Support Unit guidance.Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis (Review)